The matrix metalloproteinase gelatinase A (MMP-2) is important in normal tissue remodeling and adaptation by its ability to degrade a broad range of tissue components. However, this enzyme has also been strongly associated with abnormal tissue degradation during inflammatory diseases (arthritis and periodontal disease), tumor expansion, and formation of metastases. Since it is significant to develop methods to inhibit the gelatinase A in disease situations, it is important to understand the molecular determinants that control proteolysis by gelatinase A. Therefore, it is the aim of the proposed studies to test the hypothesis that binding of human gelatinase A to cell surfaces via the collagen binding domain of the enzyme serves to provide a reservoir of latent enzyme and plays a role in activation of the enzyme. The first goal of this proposal is to purify and microsequence a new receptor protein from the membranes of human fibroblasts which binds gelatinase A. Based on obtained protein sequence, we will design probes that will be used to screen a cDNA library. By this screening, we will isolate a clone which encodes the cell membrane protein of interest. After isolation, the coding DNA will be sequenced and characterized. Once the cDNA clone is isolated, we will construct an expression vector that can be used to produce recombinant receptor protein in E. coli. Protein expression by this approach will permit us to obtain sufficient receptor protein to verify binding of the cellular receptor to the collagen binding domain of gelatinase A and to native gelatinase A. In addition, we will be able to fully characterize the interaction between the receptor and gelatinase A. The proposed studies should define the contribution of interaction of the new receptor protein and the collagen binding domain to cell surface localization of gelatinase A. In addition, we will gain a valuable tool for future molecular and cellular studies of gelatinase A cell surface activation mechanisms.

Agency
National Institute of Health (NIH)
Institute
National Institute of Dental & Craniofacial Research (NIDCR)
Type
Small Research Grants (R03)
Project #
1R03DE012818-01
Application #
2704518
Study Section
Special Emphasis Panel (ZDE1-PW (35))
Project Start
1998-08-01
Project End
2000-07-31
Budget Start
1998-08-01
Budget End
1999-07-31
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Dentistry
Type
Schools of Dentistry
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Stanley, Corey M; Wang, Yao; Pal, Sanjay et al. (2008) Fibronectin fragmentation is a feature of periodontal disease sites and diabetic foot and leg wounds and modifies cell behavior. J Periodontol 79:861-75
Xu, Xiaoping; Chen, Zhihua; Wang, Yao et al. (2007) Inhibition of MMP-2 gelatinolysis by targeting exodomain-substrate interactions. Biochem J 406:147-55
Xu, Xiaoping; Chen, Zhihua; Wang, Yao et al. (2005) Functional basis for the overlap in ligand interactions and substrate specificities of matrix metalloproteinases-9 and -2. Biochem J 392:127-34
Xu, Xiaoping; Wang, Yao; Chen, Zhihua et al. (2005) Matrix metalloproteinase-2 contributes to cancer cell migration on collagen. Cancer Res 65:130-6
Xu, Xiaoping; Wang, Yao; Lauer-Fields, Janelle L et al. (2004) Contributions of the MMP-2 collagen binding domain to gelatin cleavage. Substrate binding via the collagen binding domain is required for hydrolysis of gelatin but not short peptides. Matrix Biol 23:171-81
Steffensen, Bjorn; Xu, Xiaoping; Martin, Pamela A et al. (2002) Human fibronectin and MMP-2 collagen binding domains compete for collagen binding sites and modify cellular activation of MMP-2. Matrix Biol 21:399-414
Hoang, A M; Klebe, R J; Steffensen, B et al. (2002) Amelogenin is a cell adhesion protein. J Dent Res 81:497-500
Steffensen, B; Hakkinen, L; Larjava, H (2001) Proteolytic events of wound-healing--coordinated interactions among matrix metalloproteinases (MMPs), integrins, and extracellular matrix molecules. Crit Rev Oral Biol Med 12:373-98